Christian [Analyst]'s questions to Amylyx Pharmaceuticals Inc (AMLX) leadership • Q2 2025
Question
An analyst named Christian asked about the impact of new endocrinology society guidelines on standardizing PBH diagnosis and sought reassurance on the durability of Avexatide's effect through the 16-week LUCIDITY trial.
Answer
Co-CEO & Co-Founder Josh Cohen explained that PBH diagnosis is straightforward once suspected and that new guidelines and inclusion in textbooks are raising awareness. Chief Medical Officer Dr. Camille Bedrosian added that based on the drug's mechanism, they do not anticipate any tachyphylaxis or loss of effect over time.